Table 1.
Characterization of studied populations and results of determination of autoantibodies and biochemical markers. ANA antibodies shown in square brackets. Values of biochemical markers above the limit of normal values are shown with a gray background, results exceeding this limit twice or more are highlighted in bold. ND—not determined, CK—creatine kinase, MYO—myoglobin. Results were evaluated on a semi-quantitative scale: + weakly positive, ++ moderately positive, +++ strongly positive.
| PTLDS Group | Control Group | ||||||
|---|---|---|---|---|---|---|---|
| Number of subjects | |||||||
| 59 | 40 | ||||||
| Average age; median of age; standard deviation | |||||||
| 45.0; 46.0; 13.2 | 42.4; 39.5; 14.5 | ||||||
| Gender ratio (Females/Males) | |||||||
| 32/27 | 30/10 | ||||||
| Myositis autoantibodies positive results | |||||||
| Gender, age | Antigen positivity | CK (µkat/L) | MYO (µg/L) | Gender, age | Antigen positivity | CK (µkat/L) | MYO (µg/L) |
| F, 28 | MDA5 + | 3.19 | 40 | F, 27 | PL-7 + | 1.41 | 21.9 |
| F, 54 | PM-Scl75 + | 1.95 | 54.1 | M, 38 | Ku + | 2.25 | 70.3 |
| M, 23 | PL-7 + | ND | ND | ||||
| M, 57 | PM-Scl100 + | 1.52 | 523 | ||||
| F, 47 | Jo-1 + (Scl-70 +) | 2.75 | 198.7 | ||||
| F, 41 | Jo-1 + | 0.65 | 22.1 | ||||
| M, 47 | PL-12 +++ | 6.14 | 53 | ||||
| F, 29 | Mi-2a +; SAE1+ | 1.37 | 29.2 | ||||
| M, 42 | Mi-2a + | 2.64 | 69,1 | ||||
| F, 39 | PM-Scl75 + | 0.7 | 27.8 | ||||
| M, 41 | Ro-52 +++ | 3.21 | 115.1 | ||||
| F, 22 | PL-7 +; Mi-2b + | 0.93 | 25.2 | ||||
| M, 41 | PM-Scl100 + | 2.62 | 312 | ||||
| M, 67 | PM-Scl75 + | 3.4 | 95.7 | ||||
| F, 61 | Mi-2a +; Ku + | 1.32 | 32.6 | ||||
| F, 57 | Mi-2a +; PL-7 + | 3.14 | 22.2 | ||||
| M, 63 | SRP ++ (AMA-M2 +++) |
0.84 | 45.9 | ||||
| F, 21 | Ku + | 1.36 | 34.1 | ||||